Arcadia Biosciences, Inc. RKDA
Arcadia Biosciences, Inc. statistics & valuation
Market cap$1.4M
P / S0.3×
P / B0.3×
Net margin-48.1%
Return on equity-56.5%
FCF margin-96.7%
Return on capital-55.7%
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -51.5% | -72.3% | -137.0% | -188.8% | -524.0% | -159.0% | -1657.9% | -1152.3% | -355.6% | -584.1% |
| Net margin | -48.1% | -139.5% | -313.9% | -207.3% | -216.2% | -57.9% | -2464.1% | -920.8% | -390.1% | -615.6% |
| FCF margin | -96.7% | -191.1% | -343.5% | -189.4% | -396.4% | -405.2% | -1597.5% | -948.2% | -348.8% | -542.2% |
| Return on assets | -35.7% | -52.1% | -71.0% | -53.2% | -33.4% | -9.8% | -88.4% | -56.1% | -94.8% | -34.7% |
| Return on equity | -56.5% | -113.1% | -108.9% | -73.1% | -47.0% | -16.3% | -346.0% | -105.2% | -196.2% | -88.4% |
| Debt / equity | — | — | — | — | 0.00× | 0.07× | 0.01× | 0.00× | 0.00× | 1.13× |
| Current ratio | 3.09 | 3.61 | 4.17 | 6.03 | 7.02 | 5.02 | 4.98 | 7.49 | 4.27 | 16.69 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.